

Oliver Schnell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3010014/publications.pdf>

Version: 2024-02-01

39
papers

2,667
citations

430874

18
h-index

361022

35
g-index

45
all docs

45
docs citations

45
times ranked

4198
citing authors

#	ARTICLE	IF	CITATIONS
1	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1100-1108.	10.7	800
2	Mapping microglia states in the human brain through the integration of high-dimensional techniques. <i>Nature Neuroscience</i> , 2019, 22, 2098-2110.	14.8	296
3	Tumor-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma. <i>Nature Communications</i> , 2019, 10, 2541.	12.8	218
4	Imaging of integrin $\alpha v \beta 3$ expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. <i>Neuro-Oncology</i> , 2009, 11, 861-870.	1.2	180
5	Spatially resolved multi-omics deciphers bidirectional tumor-host interdependence in glioblastoma. <i>Cancer Cell</i> , 2022, 40, 639-655.e13.	16.8	166
6	Expression of Integrin $\alpha v \beta 3$ in Gliomas Correlates with Tumor Grade and Is not Restricted to Tumor Vasculature. <i>Brain Pathology</i> , 2008, 18, 378-386.	4.1	161
7	Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O ⁶ -Methylguanine- α -DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized CLARIUS Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1611-1619.	1.6	151
8	Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas. <i>Nature Cancer</i> , 2021, 2, 723-740.	13.2	110
9	T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10. <i>Nature Communications</i> , 2022, 13, 925.	12.8	104
10	Microglia contribute to the propagation of A β into unaffected brain tissue. <i>Nature Neuroscience</i> , 2022, 25, 20-25.	14.8	89
11	Human organotypic brain slice culture: a novel framework for environmental research in neuro-oncology. <i>Life Science Alliance</i> , 2019, 2, e201900305.	2.8	38
12	One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned?. <i>Journal of Neuro-Oncology</i> , 2018, 140, 385-391.	2.9	31
13	Astrogliosis Releases Pro-Oncogenic Chitinase 3-Like 1 Causing MAPK Signaling in Glioblastoma. <i>Cancers</i> , 2019, 11, 1437.	3.7	28
14	Observation after surgery for low grade glioma: long-term outcome in the light of the 2016 WHO classification. <i>Journal of Neuro-Oncology</i> , 2019, 145, 501-507.	2.9	26
15	Effect of early palliative care for patients with glioblastoma (EPCOG): a randomised phase III clinical trial protocol. <i>BMJ Open</i> , 2020, 10, e034378.	1.9	26
16	Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, 1885-1897.	1.2	23
17	The integrative metabolomic-transcriptomic landscape of glioblastome multiforme. <i>Oncotarget</i> , 2017, 8, 49178-49190.	1.8	22
18	Microenvironment-Derived Regulation of HIF Signaling Drives Transcriptional Heterogeneity in Glioblastoma Multiforme. <i>Molecular Cancer Research</i> , 2018, 16, 655-668.	3.4	21

#	ARTICLE	IF	CITATIONS
19	Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme. <i>Oncotarget</i> , 2017, 8, 74170-74177.	1.8	21
20	ACTR-58. PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial. <i>Neuro-Oncology</i> , 2017, 19, vi13-vi14.	1.2	17
21	Survival and Prognostic Predictors of Anaplastic Meningiomas. <i>World Neurosurgery</i> , 2019, 131, e321-e328.	1.3	16
22	Neuropathological interpretation of stimulated Raman histology images of brain and spine tumors: part B. <i>Neurosurgical Review</i> , 2022, 45, 1721-1729.	2.4	15
23	Inhibition of metabotropic glutamate receptor III facilitates sensitization to alkylating chemotherapeutics in glioblastoma. <i>Cell Death and Disease</i> , 2021, 12, 723.	6.3	14
24	Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study. <i>Journal of Neuro-Oncology</i> , 2020, 148, 117-130.	2.9	12
25	Stimulated Raman histology in the neurosurgical workflow of a major European neurosurgical center – part A. <i>Neurosurgical Review</i> , 2022, 45, 1731-1739.	2.4	12
26	Resection of recurrent glioblastoma multiforme in elderly patients: a pseudo-randomized analysis revealed clinical benefit. <i>Journal of Neuro-Oncology</i> , 2020, 146, 381-387.	2.9	11
27	Herniation World Federation of Neurosurgical Societies Scale Improves Prediction of Outcome in Patients With Poor-Grade Aneurysmal Subarachnoid Hemorrhage. <i>Stroke</i> , 2022, 53, 2346-2351.	2.0	10
28	Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics. <i>Cell Death and Differentiation</i> , 2022, 29, 2089-2104.	11.2	10
29	Diffusion Microstructure Imaging to Analyze Perilesional T2 Signal Changes in Brain Metastases and Glioblastomas. <i>Cancers</i> , 2022, 14, 1155.	3.7	7
30	Proposed definition of competencies for surgical neuro-oncology training. <i>Journal of Neuro-Oncology</i> , 2021, 153, 121-131.	2.9	6
31	SPectroScOpic prediction of bRain Tumours (SPORT): study protocol of a prospective imaging trial. <i>BMC Medical Imaging</i> , 2020, 20, 123.	2.7	5
32	Metabolic alterations in meningioma reflect the clinical course. <i>BMC Cancer</i> , 2021, 21, 211.	2.6	5
33	MGMT promoter methylation is not correlated with integrin expression in malignant gliomas: clarifying recent clinical trial results. <i>Medical Oncology</i> , 2018, 35, 103.	2.5	2
34	Characterization of longitudinal transformation of T2-hyperintensity in oligodendroglioma. <i>BMC Cancer</i> , 2020, 20, 818.	2.6	2
35	Ultrasound Perfusion Imaging for the Detection of Cerebral Hypoperfusion After Aneurysmal Subarachnoid Hemorrhage. <i>Neurocritical Care</i> , 2022, 37, 149-159.	2.4	2
36	METB-12. METABOLIC RE-PROGRAMING MEDIATES BIDIRECTIONAL SHIFT BETWEEN TRANSCRIPTIONAL SUBCLASSES AND DRIVES TUMOR HETEROGENEITY. <i>Neuro-Oncology</i> , 2017, 19, vi131-vi131.	1.2	0

#	ARTICLE	IF	CITATIONS
37	TMIC-52. REACTIVE ASTROCYTES AID THE EVOLUTION OF IMMUNOSUPPRESSIVE ENVIRONMENT AND DRIVE ONCOGENIC SIGNALING IN GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi259-vi259.	1.2	0
38	NIMG-63. LONGITUDINAL ANALYSIS OF OLIGODENDROGLIOMA GROWTH PATTERN REVEALED SPATIAL HETEROGENEITY AND DIVERSE TREATMENT RESPONSE. Neuro-Oncology, 2019, 21, vi175-vi175.	1.2	0
39	Spatially Resolved Multi-Omics Deciphers Bidirectional Tumor-Host Interdependence in Glioblastoma. SSRN Electronic Journal, 0, , .	0.4	0